Thrombin generation and bleeding in haemophilia A

Haemophilia

Volumn 15, Issue 5, 2009, Pages 1118-1125

  Brummel Ziedins, Kathleen E ^a   Whelihan, M F ^a   Gissel, M ^a   Mann, K G ^a   Rivard, G E ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Bleeding; Haemophilia A; Phenotype; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 8; THROMBIN; TRYPSIN INHIBITOR;

ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMARTHROSIS; HEMATOMA; HEMOPHILIA A; HUMAN; MALE; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBIN TIME;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; PHENOTYPE; PLANT PROTEINS; REFERENCE VALUES; THROMBIN; THROMBOPLASTIN; WHOLE BLOOD COAGULATION TIME;

EID: 67849124907     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.01994.x     Document Type: Article

References (46)

1. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
2. Mannucci PM. Hemophilia: Treatment options in the twenty-first century. J Thromb Haemost 2003; 1: 1349-55.
3. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Haemost 2003; 29: 23-30.
4. High KA. Gene transfer as an approach to treating hemophilia. Semin Thromb Haemost 2003; 29: 107-20.
5. Lillicrap D. Gene expression: Overview and clinical implications. Vox Sang 2002; 83 (Suppl 1): 77-9.
6. VandenDriessche T, Collen D, Chuah MK. Viral vector-mediated gene therapy for hemophilia. Curr Gene Ther 2001; 1: 301-15.
7. VandenDriessche T, Collen D, Chuah KL. Gene therapy for the hemophilias. J Thromb Haemost 2003; 1: 1550-8.
8. Kleinveld HA, Andersson NE, van Voorthuiozen H, den Hartog J, de Groot PG. Determination of coagulation factor VIII activity by a chromogenic substrate method on STA, an automated coagulation analyzer. Scand J Clin Lab Invest 1999; 59: 335-41.
9. Margolis J. An improved procedure for accurate assays of factor VIII. Pathology 1979; 11: 149-59.
10. Kekwick RA, Walton PL. An assay for antihaemophilic factor (factor VIII) with some considerations affecting the establishment of a standard reference preparation. Br J Haematol 1964; 10: 299-313.
11. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations. Semin Thromb Haemost 2002; 28: 247-55.
12. Mannucci PM, Tuddenham EGD. The hemophiliacs - from royal genes to gene therapy. N Engl J Med 2001; 344: 1733-79.
13. White GC, Rosendaal FR, Aledort L. Definitions in hemophilia. Thromb Haemost 2001; 85: 560.
14. Graham JB, McLendon WW, Brinkhous KM. Mild hemophilia: An allelic form of the disease. Am J Med Sci 1953; 225: 46-53.
15. Barrowcliffe TW, Kirkwood TBL. An international collaborative assay of factor VIII clotting activity. Thromb Haemost 1978; 40: 260-71.
16. Kocoshis TA, Triplett DA. CAP survey results for factor VIII assays (1977-1978). Am J Clin Pathol 1979; 72: 346-51.
17. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38 (Suppl 4): 13-23.
18. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Haemost 2002; 28: 257-64.
19. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia 1998; 4: 641-5.
20. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
21. Al Dieri R, Peyvandi F, Santagostino E et al. The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
22. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
23. Rivard GE, Hofer A, Fan L, Amesse C. Evaluation by thromboelastography of response to B domain deleted FVIII concentrate in whole blood shows expected potency results for dosage used. Blood 2003; 120: 11.
24. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
25. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
26. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
27. Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler Thromb Vasc Biol 2003; 23: 123-9.
28. Butenas S, Branda RF, van't Veer C, Cawthern KM, Mann KG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 660-7.
29. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001; 104: 2311-7.
30. Butenas S, Cawthern KM, van't Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-22.
31. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-33.
32. Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-10.
33. Lawson JH, Krishnaswamy S, Butenas S, Mann KG. Extrinsic pathway proteolytic activity. Methods Enzymol 1993; 222: 177-95.
34. Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: Purification and characterization. Thromb Res 1980; 20: 149-62.
35. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
36. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
37. Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: Phenotypic quantitation. J Thromb Haemost 2004; 2: 281-8.
38. Brummel ZK, Rivard GE, Pouliot RL et al. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2: 1735-44.
39. Hemker HC, Giesen P, AlDieri R et al. The calibrated automated thrombogram (CAT): A universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
40. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
41. Dargaud Y, Luddington R, Baglin T. Platelet-dependent thrombography: A method for diagnostic laboratories. Br J Haematol 2006; 134: 323-5.
42. Brummel-Ziedins K, Whelihan MF, Ziedins EG, Mann KG. The resuscitative fluid you choose may potentiate bleeding. J Trauma 2006; 61: 1350-8.
43. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-34.
44. Trossaert M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: Using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2008; 6: 486-93.
45. Mann KG, Whelihan MF, Butenas S, Orfeo T. Citrate anticoagulation and the dynamics of thrombin generation. J Thromb Haemost 2007; 5: 2055-61.
46. Brummel-Ziedins K, Whelihan MF, Ziedins EG, Mann KG. The resuscitative fluid you choose may potentiate bleeding. J Trauma 2006; 61: 1350-8.